Phio Pharma Q2 net loss $2.5M; PH-762 Phase 1b trial advancing after IND clearance

Phio Pharmaceuticals Corp.

2023-Q2 EPS reported -$4.28

Net loss of $2.5M ($1.47 per share) for Q2 2023, consistent with $2.5M ($2.22 per share) in Q2 2022.
Cash $11.3M at June 30, 2023 vs $11.8M at Dec 31, 2022; R&D expenses $1.4M, up 6% YoY.
FDA cleared IND for PH-762; planning Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, Merkel cell.
Initiated collaborative Phase 1b trial with AgonOx's TIL program (AGX148) and Providence Cancer Institute.
Appointed Jennifer Phillips, Pharm.D., as VP of Regulatory Affairs and Corporate Affairs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Phio Pharmaceuticals Corp. reported quarter ended June 30, 2023 results: net income $2.5 million, or $1.47 per share.

Period: quarter ended June 30, 2023
Net income: $2.5 million, or $1.47 per share
Result: reported results

Exact text from the filing

Net loss was $2.5 million, or $1.47 per share, for the quarter ended June 30, 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-23-005515

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.